.Back to listing
Sat, Feb 08
Maker Of $1,000 Hepatitis C Pill Looks To Cut Its Cost Overseas
An effective new medicine is developed as a cure for a major disease. The drug company prices the medicine at tens of thousands of dollars for a course of treatment. How can the disease-curing medicine be made accessible to patients who need it, most of whom live in low- and middle-income countries? It’s well worth watching as drugmaker Gilead Sciences tries to solve this riddle for Solvadi, a newly approved drug for the deadly liver infection hepatitis C that afflicts more than 150 million people around the world. Read more.